Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration

OBJECTIVES: To evaluate clinical response by baseline disease duration using 2-year data from the AMPLE trial. METHODS: Patients were randomised to subcutaneous abatacept 125 mg weekly or adalimumab 40 mg bi-weekly, with background methotrexate. As part of a post hoc analysis, the achievement of val...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, Michael, Weinblatt, Michael E, Valente, Robert, Citera, Gustavo, Maldonado, Michael, Massarotti, Elena, Yazici, Yusuf, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838764/
https://www.ncbi.nlm.nih.gov/pubmed/27110385
http://dx.doi.org/10.1136/rmdopen-2015-000210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838764/
https://www.ncbi.nlm.nih.gov/pubmed/27110385
http://dx.doi.org/10.1136/rmdopen-2015-000210

Ejemplares similares